Glenmark In Talks With Three Firms To Re-license Diabetes Drug
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Glenmark Pharmaceuticals is again in discussions with at least three companies to license out its experimental DPP-4 inhibitor drug melogliptin (GRC 8200), according to a company official
You may also be interested in...
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
U.S. Court Dismisses Teva’s Patent Infringement Plea Against Dr Reddy’s Carvedilol; Dr Reddy’s May Launch Drug Soon
MUMBAI - Dr Reddy's Labs may be able to sell generic versions of GlaxoSmithKline's hypertension drug Coreg (carvedilol) in the U.S. after it settled a case against Israeli drug maker Teva for four patents of the drug
Glenmark Continues Search For New Partners As Merck Diabetes Agreement Ends, Reports Strong Q4 Earnings
MUMBAI - Glenmark Phamaceuticals said it is continuing to seek partners to develop its DPP-IV inhibitor melogliptin for type 2 diabetes treatment through outlicensing after it ended an agreement with Merck Serono to develop the drug